SAVA vs. IRWD, ELVN, ARQT, GYRE, LQDA, VRNA, INVA, COLL, ABCL, and TYRA
Should you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Ironwood Pharmaceuticals (IRWD), Enliven Therapeutics (ELVN), Arcutis Biotherapeutics (ARQT), Gyre Therapeutics (GYRE), Liquidia (LQDA), Verona Pharma (VRNA), Innoviva (INVA), Collegium Pharmaceutical (COLL), AbCellera Biologics (ABCL), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical preparations" industry.
Cassava Sciences (NASDAQ:SAVA) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, community ranking, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.
Cassava Sciences presently has a consensus target price of $131.00, indicating a potential upside of 504.52%. Ironwood Pharmaceuticals has a consensus target price of $18.40, indicating a potential upside of 212.93%. Given Cassava Sciences' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals received 409 more outperform votes than Cassava Sciences when rated by MarketBeat users. However, 66.43% of users gave Cassava Sciences an outperform vote while only 61.09% of users gave Ironwood Pharmaceuticals an outperform vote.
Cassava Sciences has a net margin of 0.00% compared to Ironwood Pharmaceuticals' net margin of -254.41%. Ironwood Pharmaceuticals' return on equity of -28.45% beat Cassava Sciences' return on equity.
In the previous week, Ironwood Pharmaceuticals had 19 more articles in the media than Cassava Sciences. MarketBeat recorded 21 mentions for Ironwood Pharmaceuticals and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 1.43 beat Ironwood Pharmaceuticals' score of 0.15 indicating that Cassava Sciences is being referred to more favorably in the media.
Cassava Sciences has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Cassava Sciences is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
38.1% of Cassava Sciences shares are held by institutional investors. 12.2% of Cassava Sciences shares are held by company insiders. Comparatively, 12.9% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Cassava Sciences has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
Summary
Ironwood Pharmaceuticals beats Cassava Sciences on 9 of the 16 factors compared between the two stocks.
Get Cassava Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cassava Sciences Competitors List
Related Companies and Tools
